Company: VERA
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000950170-25-064733
Chunk: 18

Company: Vera Therapeutics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 1
Chunk 18
---
 narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.

•Interim, initial, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.

•We face significant competition, which may result in others discovering, developing or commercializing products before or more successfully than us.

•Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays.

•Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.

•Even if any product candidate we develop receives regulatory approval, it could be subject to significant post-marketing regulatory requirements and will be subject to continued regulatory oversight.

•Biosimilars to our product candidates may provide competition sooner than anticipated.

•Unfavorable geopolitical and global economic conditions, including tariffs and trade tensions, could adversely affect our business, financial condition and results of operations.

•Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees and key consultants.

•We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.

•Our success depends on our ability to protect our intellectual property and our proprietary technologies.